Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0U0AU
|
|||
Former ID |
DIB010721
|
|||
Drug Name |
AZD-9819
|
|||
Synonyms |
Neutrophil elastase inhibitor (inhaled, COPD), AstraZeneca
Click to Show/Hide
|
|||
Indication | Chronic obstructive pulmonary disease [ICD-11: CA22; ICD-10: J44, J44.9] | Phase 1 | [1] | |
Company |
AstraZeneca plc
|
|||
Structure |
Download2D MOL |
|||
Formula |
C25H19F3N6O2
|
|||
Canonical SMILES |
CCNC(=O)C1=NC(=C(N(C1=O)C2=CC=CC(=C2)C(F)(F)F)C)C3=CC=NN3C4=CC=C(C=C4)C#N
|
|||
InChI |
1S/C25H19F3N6O2/c1-3-30-23(35)22-24(36)33(19-6-4-5-17(13-19)25(26,27)28)15(2)21(32-22)20-11-12-31-34(20)18-9-7-16(14-29)8-10-18/h4-13H,3H2,1-2H3,(H,30,35)
|
|||
InChIKey |
ZRJDPTREGVHMGQ-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 956907-23-6
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Neutrophil elastase (NE) | Target Info | Inhibitor | [2] |
KEGG Pathway | Transcriptional misregulation in cancer | |||
Systemic lupus erythematosus | ||||
Pathway Interaction Database | Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | |||
C-MYB transcription factor network | ||||
Reactome | Collagen degradation | |||
Degradation of the extracellular matrix | ||||
Activation of Matrix Metalloproteinases | ||||
WikiPathways | Hair Follicle Development: Cytodifferentiation (Part 3 of 3) | |||
Human Complement System | ||||
Degradation of collagen |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT01166698) Single Centre, Double-blind, Single and Multiple Ascending Inhaled Doses of AZD9819 in Healthy Subjects. U.S. National Institutes of Health. | |||
REF 2 | Lipid Peroxide-Mediated Oxidative Rearrangement of the Pyrazinone Carboxamide Core of Neutrophil Elastase Inhibitor AZD9819 in Blood Plasma Samples. Drug Metab Dispos. 2015 Oct;43(10):1441-9. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.